Response by Filippatos et al to Letter Regarding Article, “Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes”-Reference-Cited by-同舟云学术

Response by Filippatos et al to Letter Regarding Article, “Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes”

Published:2021-09-14 Issue:11 Volume:144 Page:
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Filippatos Gerasimos¹,Agarwal Rajiv²,Bakris George³,Anker Stefan⁴,

Affiliation:

1. National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Greece (G.F.).

2. Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis (R.A.).

3. Department of Medicine, University of Chicago Medicine, IL (G.B.).

4. Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin (S.A.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055066

Reference5 articles.

1. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes

2. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

3. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

4. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

5. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes;Diabetes mellitus;2023-12-13

2. Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease;European Medical Journal;2023-03-16

3. Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD;Clinical Pharmacokinetics;2022-05-05

4. Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage;Current Hypertension Reports;2022-01

5. Novel Treatments and the Future of DKD: What Is on the Horizon?;Diabetes and Kidney Disease;2022